Responses
Other responses
Jump to comment:
- Published on: 18 April 2016
- Published on: 18 April 2016
- Published on: 18 April 2016Portopulmonary hypertension in cirrhosis- the pathogenetic challengeShow More
Dear Editor
We would like to thank Dr Pellicelli and his group for their interest [1] in our paper on portopulmonary hypertension in cirrhosis with refractory ascites.[2]
We acknowledge that our proposal suggesting the role of endothelin 1 (ET-1) in the pathogenesis of porto-pulmonary hypertension is based on a small number of patients. However, the strong association between the elevated ET-1 levels in t...
Conflict of Interest:
None declared. - Published on: 18 April 2016Cytokines in Portopulmonary hypertensionShow More
Dear Editor
I rise some questions about the article of Benjaminov et al. published on your journal.[1]
Although the role of endothelin-1 in portopulmonary hypertension has been suggested by many clinicians and is timely, as well as clinically important, different issues remain based upon the very limited data (n=10 portopulmonary patients)presented in this study. Furthermore it is very difficult t...
Conflict of Interest:
None declared.